Additional file 3 of The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial

Additional file 3: Table S1. 24-h cough monitoring: Cough count [1/hour]. Table S2. 24-h cough frequency: Subgroup analyses by baseline cough count (Bayesian mixed model). Table S3. 24-h cough frequency: Responder rates for different change thresholds. Table S4. VAS cough severity: Responder rates. Table S5. Treatment-emergent adverse events observed in > 5% of patients. Table S6. Cough frequency: Subgroup analyses by occurrence of taste-related adverse events (Bayesian mixed model). Table S7. Cough severity (VAS): Subgroup analyses by occurrence of taste-related adverse events (Bayesian mixed model). Figure S1. Plasma concentration–time curves for filapixant after multiple administrations.